A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520519-14-00

Acronym

D7960C00015

Enrollment

3531

Registered

2025-08-26

Start date

2025-09-03

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Cardiovascular Disease

Brief summary

Time to first event of any component of MACE PLUS

Detailed description

Time to first event of any component of 3P MACE, Time to first event of any component of MACE PLUS in participants with a prior history of ASCVD, Time to first event of MI, Time to first event of urgent coronary revascularisation, Time to CV death, Time to first event of MALE, Time to all-cause mortality

Interventions

DRUGAZD0780

DRUGAZD0780 placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to first event of any component of MACE PLUS	—

Secondary

Measure	Time frame
Time to first event of any component of 3P MACE, Time to first event of any component of MACE PLUS in participants with a prior history of ASCVD, Time to first event of MI, Time to first event of urgent coronary revascularisation, Time to CV death, Time to first event of MALE, Time to all-cause mortality	—

Countries

Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Poland, Romania, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026